Sign In
Buy VRTX
$441.74
+13.40 (+3.13%)
At Close: Jun 04, 2026
Investing in biotech outside of weight-loss drugs
06:19pm, Monday, 05'th Aug 2024
GLP-1 weight-loss drugs have pushed the biotech sector to new heights as demand steadily increases. But despite the drugs' popularity, there are other investment opportunities within the biotech secto
Prediction: These Could Be the Best-Performing Growth Stocks Through 2030
06:55am, Monday, 05'th Aug 2024
These growth stocks are leading in their respective markets. Vertex Pharmaceuticals is the dominant force in the cystic fibrosis treatment industry, but it is in the midst of a multiyear period during
3 Biotech Stocks on Track for 50% Returns (or More) by 2028
01:33pm, Sunday, 04'th Aug 2024
The biotech industry, often recognized for its rapid innovation, can set investors up for outsized returns in the stock market. However, not all biotech companies have the capability of doing so.
3 Unstoppable Stocks to Buy in August
07:45am, Saturday, 03'rd Aug 2024
Novo Nordisk is big but has plenty of room to grow. Vertex Pharmaceuticals' existing products and pipeline programs give it multiple growth catalysts.
Prediction: 2 Stocks That Will Be Worth More Than Johnson & Johnson 10 Years From Now
06:38am, Saturday, 03'rd Aug 2024
Johnson & Johnson hasn't performed that well in the past decade. By contrast, Vertex Pharmaceuticals and Intuitive Surgical have been exceptional.
Compared to Estimates, Vertex (VRTX) Q2 Earnings: A Look at Key Metrics
07:01pm, Friday, 02'nd Aug 2024
Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street es
Vertex Raises Guidance Despite Q2's Bottom-Line Losses
02:48pm, Friday, 02'nd Aug 2024
Product revenues increased by 6% to $2.65 billion, in line with market expectations. Management raised full-year product revenue guidance by $100 million.
3 Biotech Stocks That Could Have Investors Grinning Soon
01:54pm, Friday, 02'nd Aug 2024
Investing in biotech stocks is a thrilling ride. These innovative businesses developing breakthrough drugs can generate enormous profits for investors but also destroy significant value if their inves
Vertex Pharmaceuticals Lifts Annual Guidance, Positive Growth For Its Cystic Fibrosis Franchise And Pain Management Pipeline
01:48pm, Friday, 02'nd Aug 2024
Thursday, Vertex Pharmaceuticals Incorporated VTRX reported second-quarter revenues of $2.65 billion, almost in line with the consensus of estimate of $2.66 billion.
Vertex (VRTX) Q2 Loss Wider Than Expected, '24 Sales View Raised
11:05am, Friday, 02'nd Aug 2024
Vertex (VRTX) incurs a wider-than-expected loss in the second quarter while sales come in line with estimates. Vertex raises its full-year product revenue guidance.
Should You Invest in Vertex (VRTX) Based on Bullish Wall Street Views?
10:32am, Friday, 02'nd Aug 2024
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analy
Vertex Pharma: Driving Growth Through Suzetrigine And Next-Gen Cystic Fibrosis Treatment
08:30am, Friday, 02'nd Aug 2024
Vertex Pharmaceuticals has consistently outperformed the S&P 500 and iShares Biotechnology ETF, reflecting its robust growth and market position. VRTX's diversified pipeline includes cystic fibrosis t
Should Investors Worry About Vertex Pharmaceuticals $3.6 Billion Q2 Loss? Not Even for a Second.
05:50am, Friday, 02'nd Aug 2024
There's a simple explanation for Vertex's glaring Q2 loss. The company raised its full-year product revenue guidance.
Vertex Pharmaceuticals, Inc. (VRTX) Q2 2024 Earnings Call Transcript
08:37pm, Thursday, 01'st Aug 2024
Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Reshma Kewalramani - Chief Executive Officer, President Stuart Arbuckle - Ch
Vertex Pharmaceuticals (VRTX) Reports Q2 Loss, Misses Revenue Estimates
06:15pm, Thursday, 01'st Aug 2024
Vertex Pharmaceuticals (VRTX) came out with a quarterly loss of $12.83 per share versus the Zacks Consensus Estimate of a loss of $11.50. This compares to earnings of $3.89 per share a year ago.
